Multiple Sclerosis and the Comparative Value Disease Modifying Therapy Report of the Institute for Clinical and Economic Review (ICER)

INNOVATIONS in pharmacy
doi 10.24926/21550417.1358
Full Text
Abstract

Available in full text

Date
Authors
Publisher

University of Minnesota

Related search

Multiple Sclerosis Disease-Modifying Therapy and Pregnancy

Multiple Sclerosis
Neurology
2016English

Php294 - A Review of Recent Appraisals From the Institute for Clinical and Economic Review: How Important Is the Icer?

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Different Values in Cost-Effectiveness Research: Institute for Clinical and Economic Review (ICER) VS. The National Institute for Care Excellence (NICE)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Infections in Patients With Multiple Sclerosis: Implications for Disease-Modifying Therapy

Acta Neurologica Scandinavica
MedicineNeurology
2017English

Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis and Future Directions for Multiple Sclerosis Therapeutics

Archives of Neurology
1999English

Disease-Modifying Therapy in Multiple Sclerosis: Two Guidelines (Almost) Passing in the Night

Multiple Sclerosis
Neurology
2018English

Clinically Isolated Syndrome: Prognostic Markers for Conversion to Multiple Sclerosis and Initiation of Disease-Modifying Therapy

Clinical Neurology
Neurology
2011English

Disease-Modifying Therapy Adherence and Associated Factors in a National Sample of Medicare Patients With Multiple Sclerosis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2020English

Price Analysis of Multiple Sclerosis Disease-Modifying Therapies Marketed in the US

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy